News & Events

Viveve System -- Non-Surgical Treatment for Vaginal Laxity -- Now Available in 51 Countries Throughout the World

SUNNYVALE, CA -- (Marketwired) -- 03/08/16 -- Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced the expansion of its commercial availability into Latin America through a distribution partnership with HV Medical, an esteemed supplier of medical products headquartered in São Paulo, Brazil. Under the terms of the agreement HV Medical will have distribution rights for the Viveve System throughout Brazil.

"We're excited about entering the Latin American market, particularly in Brazil, which is the largest market for aesthetic medical procedures in the world. This relationship represents a significant expansion of our rapidly growing global commercialization effort," said Patricia Scheller, chief executive officer of Viveve. "The combination of our technology with HV Medical's extensive experience in Brazil will pave the way for widespread availability of the Viveve Treatment while also ensuring that physicians receive the best possible training and ongoing support as they begin offering the only clinically proven, non-surgical treatment for vaginal laxity."

HV Medical, a distributor of innovative medical technologies and products, has established an excellent reputation in Brazil. With an extensive range of high quality products and services, HV Medical delivers complete solutions and customized treatments to physicians and medical facilities. "We are happy to be able to add the Viveve System, a safe and clinically proven device to our portfolio," said Newton Martins, vice president of HV Medical. "Vaginal laxity is a common and troublesome condition for women, and the fact that there is now an effective non-surgical approach, involving just one pain-free out-patient procedure, will be welcome news to physicians and their patients."

Viveve now has 17 exclusive partnerships covering distribution of the Viveve System in 51 countries around the world, with regulatory clearance for the technology in 22 of those countries:

GEOGRAPHIC REGION	DISTRIBUTION COVERAGE	REGULATORY CLEARANCE
North America	1	1
Latin America	1	-
Europe	28	18
Asia Pacific	11	3
Middle East	10	-
TOTAL	51	22

 

 

 

 

 

 

 

 

 

 

 

About Viveve

Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc.

Contact:

Amato and Partners, LLC

Investor Relations Counsel

90 Park Avenue. 17th Floor

New York, NY 10016

212.430.0360

admin@amatoandpartners.com

 

Source: Viveve Medical, Inc.